Industry Symposium: Clinical controversies in HER2+ early breast cancer
Supported by Roche
Roche

Friday, October 12, 2018
11:30 – 12:30

 Chairpersons Fran Boyle, Australia                                                                                                                                                                      Hall B
Catherine Shannon, Australia   ­                                                                                                                                                                        
11:30 – 11:45 Neo-adjuvant therapy in HER2 positive disease
Javier Cortes, Spain
11:45 – 12:15
11:45
11:55
12:05
DEBATE: That all high-risk adjuvant HER2 patients should receive dual antibody therapy
Yes: Javier Cortes, Spain
No: Nicholas Wilcken, Australia
Discussion
12:15 – 12:30 Case studies: HER2 +ve neo-adjuvant and adjuvant setting
Moderator: Fran Boyle, AustraliaJavier Cortes, Spain
Richard de Boer, Australia
Nicholas Wilcken, Australia